C4 Therapeutics, Inc. Share-based Payment Arrangement, Expense
C4 Therapeutics, Inc. (CCCC) reported Share-based Payment Arrangement, Expense of $3.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-11
- C4 Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $3.04M, a 39.18% decline year-over-year.
- C4 Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $2.67M, a 51.50% decline year-over-year.
- C4 Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $4.01M, a 51.34% decline year-over-year.
- C4 Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $4.59M, a 47.99% decline year-over-year.
- C4 Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2025 was $19.10M, a 35.61% decline from fiscal 2024.
- C4 Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2024 was $29.66M, a 8.91% increase from fiscal 2023.
- C4 Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2023 was $27.23M, a 9.27% decline from fiscal 2022.
- C4 Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2022 was $30.02M, a 39.53% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.04M 10-Q · filed 2026-08-11 | $5.71M 10-Q · filed 2026-08-11 | $9.71M derived: sum of 3 quarters · filed 2026-08-11 | $14.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.67M 10-Q · filed 2026-05-12 | $6.68M derived: sum of 2 quarters · filed 2026-05-12 | $11.27M derived: sum of 3 quarters · filed 2026-05-12 | $16.26M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $4.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.60M derived: sum of 2 quarters · filed 2026-02-26 | $13.59M derived: sum of 3 quarters · filed 2026-08-11 | $19.10M 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.59M 10-Q · filed 2025-11-06 | $9.59M derived: sum of 2 quarters · filed 2026-08-11 | $15.09M 10-Q · filed 2025-11-06 | $23.33M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $4.99M 10-Q · filed 2026-08-11 | $10.50M 10-Q · filed 2026-08-11 | $18.73M derived: sum of 3 quarters · filed 2026-08-11 | $27.57M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $5.51M 10-Q · filed 2026-05-12 | $13.74M derived: sum of 2 quarters · filed 2026-05-12 | $22.57M derived: sum of 3 quarters · filed 2026-05-12 | $28.95M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $8.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $17.07M derived: sum of 2 quarters · filed 2026-02-26 | $23.45M derived: sum of 3 quarters · filed 2026-02-26 | $29.66M 10-K · filed 2026-02-26 |
| 2024-09-30 | $8.83M 10-Q · filed 2025-11-06 | $15.21M derived: sum of 2 quarters · filed 2025-11-06 | $21.43M 10-Q · filed 2025-11-06 | $27.79M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $6.38M 10-Q · filed 2025-08-07 | $12.60M 10-Q · filed 2025-08-07 | $18.95M derived: sum of 3 quarters · filed 2025-08-07 | $27.16M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $6.21M 10-Q · filed 2025-05-07 | $12.57M derived: sum of 2 quarters · filed 2025-05-07 | $20.77M derived: sum of 3 quarters · filed 2025-05-07 | $27.20M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $6.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $14.56M derived: sum of 2 quarters · filed 2025-02-27 | $20.98M derived: sum of 3 quarters · filed 2025-02-27 | $27.23M 10-K · filed 2025-02-27 |
| 2023-09-30 | $8.20M 10-Q · filed 2024-10-31 | $14.63M derived: sum of 2 quarters · filed 2024-10-31 | $20.88M 10-Q · filed 2024-10-31 | $27.80M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $6.42M 10-Q · filed 2024-08-01 | $12.68M 10-Q · filed 2024-08-01 | $19.59M derived: sum of 3 quarters · filed 2024-08-01 | $25.61M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $6.25M 10-Q · filed 2024-05-08 | $13.17M derived: sum of 2 quarters · filed 2024-05-08 | $19.18M derived: sum of 3 quarters · filed 2024-05-08 | $27.33M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $6.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $12.93M derived: sum of 2 quarters · filed 2024-02-22 | $21.08M derived: sum of 3 quarters · filed 2024-02-22 | $30.02M 10-K · filed 2024-02-22 |
| 2022-09-30 | $6.01M 10-Q · filed 2023-11-01 | $14.16M derived: sum of 2 quarters · filed 2023-11-01 | $23.10M 10-Q · filed 2023-11-01 | $29.45M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $8.15M 10-Q · filed 2023-08-08 | $17.09M 10-Q · filed 2023-08-08 | $23.44M derived: sum of 3 quarters · filed 2023-08-08 | $29.52M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $8.94M 10-Q · filed 2023-05-04 | $15.29M derived: sum of 2 quarters · filed 2023-05-04 | $21.38M derived: sum of 3 quarters · filed 2023-05-04 | $26.61M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $6.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $12.44M derived: sum of 2 quarters · filed 2023-02-23 | $17.67M derived: sum of 3 quarters · filed 2023-02-23 | $21.51M 10-K · filed 2023-02-23 |
| 2021-09-30 | $6.09M 10-Q · filed 2022-11-03 | $11.31M derived: sum of 2 quarters · filed 2022-11-03 | $15.16M 10-Q · filed 2022-11-03 | $17.88M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $5.23M 10-Q · filed 2022-08-04 | $9.07M 10-Q · filed 2022-08-04 | $11.79M derived: sum of 3 quarters · filed 2022-08-04 | $12.23M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $3.85M 10-Q · filed 2022-05-05 | $6.56M derived: sum of 2 quarters · filed 2022-05-05 | $7.00M derived: sum of 3 quarters · filed 2022-05-05 | $7.16M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $3.15M derived: sum of 2 quarters · filed 2022-02-24 | $3.32M derived: sum of 3 quarters · filed 2022-02-24 | $3.43M 10-K · filed 2022-02-24 |
| 2020-09-30 | $436.00K 10-Q · filed 2021-11-10 | $597.00K derived: sum of 2 quarters · filed 2021-11-10 | $713.00K 10-Q · filed 2021-11-10 | $1.44M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $161.00K 10-Q · filed 2021-08-11 | $277.00K 10-Q · filed 2021-08-11 | $1.01M derived: sum of 3 quarters · filed 2022-02-24 | $1.63M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $116.00K 10-Q · filed 2021-05-13 | $845.00K derived: sum of 2 quarters · filed 2022-02-24 | $1.47M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $729.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.36M derived: sum of 2 quarters · filed 2022-02-24 | $1.64M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $627.00K 10-Q · filed 2020-11-12 | $913.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |